Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,201,643 | $116,995,309 | +50% | 0.06% |
| 2. | Holocene Advisors Brandon Haley | 2,145,181 | $113,994,918 | +190% | 0.28% |
| 3. | AQR Capital Management Cliff Asness | 1,753,283 | $93,169,430 | +74% | 0.08% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,234,088 | $65,579,436 | +130% | 0.35% |
| 5. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,018,183 | $54,106,239 | -13% | 1.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.35 | 19,500 | $1,001,325.00 | 1,074,191 | 2024-11-13 | Filing | |
| $37.71 | 2,500 | $94,275.00 | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | $138,400.00 | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | $90,500.00 | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | $60,613.20 | 105,927 | 2016-08-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.02 | 1,485 | $62,399.70 | 59,962 | 2025-08-13 | Filing | |
| $53.20 | 3,207 | $170,612.40 | 72,759 | 2025-06-13 | Filing | |
| $70.00 | 929 | $65,030.00 | 12,758 | 2024-10-08 | Filing | |
| $70.00 | 929 | $65,030.00 | 13,687 | 2024-09-18 | Filing | |
| $60.15 | 67 | $4,030.05 | 44,644 | 2024-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 26,892,316 | $1,429,057,696 | 0.08% | |
| 2. | 18,200,022 | $967,153,882 | 0.14% | |
| 3. | 17,907,459 | $951,602,371 | 0.02% | |
| 4. | 12,003,790 | $637,881,401 | 0.12% | |
| 5. | 10,532,600 | $559,702,379 | 0.01% |
News See All
Will Exact Sciences Corporation (EXAS) Continue to Penetrate the Market with Its Cologuard Test?
Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Exact Sciences' Oncodetect MRD Test Gains Medicare Coverage for Colorectal Cancer
Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.
Exact Sciences Corporation (NASDAQ:EXAS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Exact Sciences Corporation (EXAS) Slid on Fear of Competition
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 High PE Stocks Insiders Are Buying
Insider buying represents one of the most reliable signals that investors and analysts use to gauge the business outlook of the company.
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kate, and I will be your conference operator today.
Billionaire Hedge Funds
